CD274 and non-small cell lung carcinoma: Meta-analyses of previous studies have demonstrated that NSCLC patients with a NLR of ≥5 (vs. <5) receiving PD-1 inhibitors (vs. PD-L1 inhibitors) or achieving response to ICIs (vs. non-responders) were at a higher risk of developing irAEs [9].